ATOS News and Press, Atossa Therapeutics Inc. From 04/29/24

LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las Vegas, NV. Event website: https://planetmi...

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-...

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in com...

2024-04-09 14:37:37 ET More on Atossa Therapeutics ATOS, SMR and EIGR are among pre market gainers Atossa climbs after cancer therapy update Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Fi...

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The ...

2024-04-05 08:34:13 ET More on premarket gainers & stock NuScale Power Shows Too Many Red Flags NuScale Power: Attractive, Yet High-Risk Nuclear Energy Business NuScale Power Corporation (SMR) Q3 2023 Earnings Call Transcript EIGR, ADXN and BROG are among...

2024-04-01 16:41:34 ET More on Atossa Therapeutics Atossa climbs after cancer therapy update Atossa spikes as H.C. Wainwright starts at Buy on lead asset Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeuti...

Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 First patient dosed in new Phase 2 breast cancer prevention study Data from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual Meeting Ended 2023 with $88...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

2024-03-19 15:51:38 ET More on Atossa Therapeutics Atossa spikes as H.C. Wainwright starts at Buy on lead asset Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therap...